To identify mechanisms of T cell restimulation in the tumour, we capitalized on matched pairs of tumour models that were derived by exposing targeted therapy-naive (NTT) BrafV600E-driven melanoma models to MAPK pathway inhibitors (BRAF inhibitor (BRAFi), and BRAFi and MEK inhibitor (BRAFi/MEKi)) until they acquired resistance (RTT). This evidence concerns the gene MAP2K7 and neoplasm.